

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
04 August 2022 (04.08.2022)



(10) International Publication Number
WO 2022/162163 A1

(51) International Patent Classification:

C07D 241/20 (2006.01) A61K 31/4965 (2006.01)
A61P 11/00 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2022/052084

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

(22) International Filing Date:

28 January 2022 (28.01.2022)

(25) Filing Language:

English

Published:

- with international search report (Art. 21(3))

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2021/052209

29 January 2021 (29.01.2021) EP

PCT/EP2021/082836

24 November 2021 (24.11.2021) EP

(71) Applicant: ACTELION PHARMACEUTICALS LTD

[CH/CH]; Gewerbestrasse 16, 4123 Allschwil (CH).

(72) Inventors: VANIERSCHOT, Ronny; c/o Janssen Phar-

maceutica NV, Turnhoutseweg 30, 2340 Beerse (BE).

COLLAS, Alain; c/o Janssen Pharmaceutica NV, Turn-

houtseweg 30, 2340 Beerse (BE). LEYS, Carina; c/

o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340

Beerse (BE). VAN MECHELEN, Kore; c/o Janssen Phar-

maceutica NV, Turnhoutseweg 30, 2340 Beerse (BE).

(74) Agent: RUHLMANN, Eric; c/o Actelion Pharmaceuticals

Ltd, Gewerbestrasse 16, 4123 Allschwil (CH).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,

TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: PROCESS FOR MANUFACTURING A DIPHENYLPYRAZINE DERIVATIVE

(57) Abstract: The present invention relates to a process for the manufacturing of calcium;{4-[(5, 6- diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetate, or a pharmaceutically acceptable hydrate or solvate thereof. Moreover, it relates to calcium;{4-[(5,6- diphenylpyrazin-2- yl)(propan-2-yl)amino]butoxy}acetate with high purity, as well as to crystalline forms of calcium;{4-[(5,6- diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetate and hydrates thereof. Furthermore, the invention relates to the use of calcium;{4-[(5, 6- diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetate for the treatment or prevention of e.g. pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).

WO 2022/162163 A1